Key takeaways
- Novo Nordisk will discontinue Saxenda (liraglutide) in early 2027 due to declining sales.
- Saxenda is a first-generation daily GLP-1 with lower efficacy (8% weight loss) than weekly alternatives.
- Telehealth buyers are shifting entirely to weekly options like Wegovy, Zepbound, or compounded medications.
- The retirement of Saxenda allows Novo Nordisk to focus manufacturing resources on higher-demand weekly medications.
What happened
Novo Nordisk has announced plans to discontinue its older GLP-1 weight-loss injection, Saxenda (liraglutide), in early 2027. According to a report by MedPage Today, the Danish drugmaker decided to retire the medication due to declining sales.
Why it matters
For US buyers shopping for weight-loss medications through telehealth, the removal of Saxenda marks the end of an era for first-generation GLP-1 therapies. Approved by the FDA for chronic weight management in 2014, Saxenda has long served as a backup option for patients facing insurance denials or shortages of newer medications. However, its daily injection schedule, lower clinical efficacy, and high retail price make it increasingly obsolete in a market dominated by highly effective weekly options.
As Novo Nordisk phases out Saxenda, consumers will transition toward modern weekly formulations like Wegovy and Zepbound, or turn to compounded alternatives. This decision simplifies the choices available on telehealth platforms but also pressures patients currently utilizing Saxenda to consult their healthcare providers to formulate a transition plan.
What the data says
Introduced over a decade ago, Saxenda is a daily subcutaneous injection of liraglutide. In clinical trials, it typically yielded an average weight loss of approximately 8% of body weight. This efficacy has been vastly outpaced by second-generation, weekly injections:
- Wegovy (semaglutide): Administered once weekly, delivering an average of 15% weight loss.
- Zepbound (tirzepatide): Administered once weekly, achieving up to 20.9% average weight loss in clinical trials.
Financially, Saxenda carries a hefty list price of approximately $1,349 per month. Because it requires a daily injection, patients must manage 30 needles monthly, compared to just four single-use pens for weekly alternatives. With declining sales reflecting consumer preference for weekly dosing and superior weight reduction, Novo Nordisk’s decision to cease manufacturing by early 2027 reflects a calculated shift in manufacturing resources toward its high-demand semaglutide pipeline.
How it compares
For cash-pay telehealth buyers, Saxenda has rarely made financial or clinical sense in recent years. At a retail price exceeding $1,300 per month, it costs roughly the same as brand-name Wegovy and Zepbound, which retail for approximately $1,350 and $1,060 per month, respectively, before manufacturer savings cards.
When comparing these options on online platforms, the value proposition leans heavily toward modern medications:
- Dosing Frequency: Saxenda requires 365 injections per year. Wegovy and Zepbound require only 52.
- Tolerability: While all GLP-1 medications share common gastrointestinal side effects, managing daily fluctuations can be more taxing for some patients compared to the steady, weekly release of newer options. For more details on managing side effects, see our guide on GLP-1 side effects.
- Telehealth Availability: Most top-tier telehealth providers featured on our provider directory have already phased out Saxenda programs, preferring to prescribe weekly semaglutide or tirzepatide due to better patient compliance and superior weight-loss outcomes.
How this fits the bigger picture
The retirement of Saxenda is a natural milestone in the rapid evolution of the medical weight-loss market. Novo Nordisk is facing unprecedented demand for Wegovy, leading to historic manufacturing constraints. By winding down Saxenda production, the company can free up valuable filling and packaging capacity to help ease the ongoing weekly GLP-1 supply crunch.
This transition comes at a time when the regulatory and clinical landscape for pediatric and adolescent weight-loss treatments is also shifting. For example, clinical data showing that Wegovy reverses obesity in 40% of kids has accelerated the adoption of weekly options for younger patients. Conversely, global health organizations are urging caution, as seen when the WHO issued pediatric obesity guidelines that emphasize lifestyle interventions over immediate drug therapy for younger adolescents.
For patients who cannot access or afford brand-name weekly injectables, the telehealth market has increasingly filled the void with compounded alternatives. To understand how these customized preparations stack up against commercial brands, buyers often compare compounded vs. brand-name semaglutide to weigh safety, regulatory status, and cost.
What happens next
Patients currently taking Saxenda do not need to panic, as the discontinuation is set for "early 2027," giving individuals ample time to transition. Over the next several months, telehealth providers and local clinics will likely transition existing Saxenda patients to weekly alternatives.
If you are currently on Saxenda, you should expect your provider to discuss switching to Wegovy or Zepbound, or exploring compounded options if insurance coverage is an issue. To explore current pricing, telehealth platforms, and clinical paths for weekly weight-loss medications, you can use our interactive comparison tool.
Disclaimer: CompareRx does not provide medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication regimen.